ClinicalTrials.gg
Not yet recruitingNCT07568535Updated May 5, 2026

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease

A Phase 3 interventional study of Remestemcel-L-rknd and Placebo in GVHD - Graft-Versus-Host Disease, sponsored by Mesoblast, Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Mesoblast, Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a randomized, double-blind, placebo-controlled, multicenter Phase III trial to compare the efficacy and safety of remestemcel-L-rknd (remestemcel-L), ex-vivo cultured adult human mesenchymal stromal cells (MSC), combined with ruxolitinib vs. ruxolitinib combined with placebo as second-line therapy in adult patients with Grade III-IV steroid-refractory acute graft-versus-host disease (SR-aGVHD).

02

Conditions studied

  • GVHD - Graft-Versus-Host Disease

Browse trials for

03

In context

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

This study's planned enrollment of 180 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.

Browse Graft vs Host Disease studies →

Lead sponsor

Mesoblast, Ltd. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older at the time of enrollment.
  2. Able to take oral medications
  3. Have Grade III-IV SR-aGVHD at the time of enrollment, defined as aGVHD resistant to high dose at a dose of ≥ 1 mg/kg/day methylprednisolone (or equivalent), given alone or in combination with prophylaxis agents such as CNI, mTOR inhibitor, or MMF.

    1. The minimum time between the initiation of high-dose corticosteroids and enrollment is 3 days if aGVHD has progressed in at least one organ regardless of improvement in other organs, OR
    2. Minimum time of 5 days for aGVHD showing no improvement in GI or liver symptoms, OR
    3. Recurrence of Grade III-IV aGVHD after an initial response to steroid therapy.
  4. Prior use of ruxolitinib is permissible in the following cases:

    1. If no more than 2 doses of ruxolitinib were taken for aGVHD treatment prior to enrollment.
    2. If there was prior use of ruxolitinib for GVHD prophylaxis. If aGVHD developed while on ruxolitinib for GVHD prophylaxis or within 3 days of its discontinuation, the patient is not eligible.
  5. Evident myeloid and engraftment. (ANC) > 1000/mm3 and platelets ≥ 20,000/ mm3. Use of growth factor supplementation and transfusion support is allowed.
  6. Minimum performance score of 30 at the time of study entry.
  7. Patient (or legal representative where appropriate) must be capable of providing written /assent.
  8. Female patients of must use a medically accepted method of and must agree to continue use of this method for the entire duration of study participation. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device, or steroid contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
  9. Male patients with partners of childbearing potential must agree to use adequate contraception (barrier method with spermicide or abstinence) for the entire duration of study participation.
  10. Willing and able to comply with study requirements, remain at the clinic, and return to the clinic for the follow-up evaluation, as specified in this protocol during the study period.

Exclusion criteria

Exclusion Criteria:

  1. Underwent second hematopoietic cell transplantation within six months from the first transplant.
  2. Received systemic treatment for aGVHD other than +/- agents used for aGVHD prophylaxis (e.g., CNIs, mTOR inhibitor, and/or MMF).
  3. Respiratory disease requiring continuous positive pressure ventilation or intubation. Patients who need intermittent continuous positive airway pressure (e.g., during sleep) are eligible.
  4. Any underlying or current medical or psychiatric condition that, in the opinion of the investigator, would interfere with the evaluation of the patient.
  5. Post-transplant morphologic [defined as > 5% blasts on bone marrow examination and/or extramedullary relapse].
  6. Donor leukocyte infusion (DLI) for treatment of malignant disease relapse. Patients who received DLI for indications other than relapse, including for treatment of minimal residual disease (MRD) and mixed chimerism, are eligible.
  7. Prior treatment with any mesenchymal lineage cells, including remestemcel-L.
  8. Active or inadequately treated latent infection with Mycobacterium tuberculosis (i.e., tuberculosis).
  9. Female patients who are pregnant, lactating, or planning a pregnancy during the expected remestemcel-L treatment period.
  10. Concurrently receiving an agent, device or procedure. An investigational agent, device or procedure is defined as having no known FDA-approved indications. Any prior and/or current participation in a clinical trial of an investigational medicinal product (IMP) that is registered and being used off label requires review by the study's Protocol Officer, Protocol Chairs, and Sponsor prior to enrollment.
  11. Known to DMSO or to porcine or bovine proteins.
  12. Requiring vasopressor support.
  13. Uncontrolled infections. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Persistent fever without other signs or symptoms will not be interpreted as progressing infection. Progression of infection is defined as: hemodynamic instability attributable to sepsis OR new symptoms attributable to infection OR worsening physical signs attributable to infection OR worsening radiographic findings attributable to infection. Patients with radiographic findings attributable to infection within 4 weeks prior to enrollment must have a repeat radiographic exam within one week of enrollment that documents stable or improved findings.
  14. Estimated less than 15 mL/min or those requiring hemodialysis.
  15. liver disorders or greater than 3 mg/dl not attributable to aGVHD or Gilbert's.
  16. Moderate to severe cGVHD that require systemic treatment. Chronic that is not requiring systemic therapy is allowed.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Remestemcel-L-rknd

    Remestemcel-L will be administered as intravenous infusions

    Drug: Remestemcel-L-rknd

  • Placebo comparator
    Placebo

    PTM will be administered as intravenous infusions

    Other: Placebo

Interventions

  • Remestemcel-L is comprised of ex-vivo cultured adult human MSC

  • OtherPlacebo

    Placebo is infusion based to be given at the same points as remestemcel-L-rknd

06

What researchers measure

Primary outcomes

  1. Overall response

    The primary clinical endpoint is overall response at Day 28 post-randomization. Overall response is defined as achieving a PR or CR on Day 28 post-randomization without requirement for new intervening systemic immunosuppressive therapies

    Time frame: 28 days post randomization

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Feb 2028, 17 months later.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 5, 2026
StartEst.
Aug 31, 2026
Primary completionEst.
Feb 28, 2028
CompletionEst.
Jul 2028
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07568535
Lead sponsor
Mesoblast, Ltd.
Responsible party
Sponsor
First posted
May 5, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
Feb 28, 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
May 5, 2026

Study contacts

Teresa Montagut, MD
Contact
Teresa.Montagut@mesoblast.com
19173294933

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remestemcel-l

Start the discussion